2[1]Feher M, Elkeles R.Lipid modification and coronary heart disease in type 2 diabetes:different from the general population.Heart,1999,81:10-11. 被引量：1
3[2]Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III).JAMA,2001,285:2486-2497. 被引量：1
4[3]Holman R. The UKPDS: implications for the dyslipidaemic patient. Acta Diabetol,2001,38: S9-14. 被引量：1
5[4]Taskinen MR, Smith U. Lipid disorders in NIDDM: implications for treatment. Journal of Internal Medicine,1998,244:361-370. 被引量：1
6[5]Barnett AH.Dyslipidaemia in diabetes-A GP guide.Practitioner,2002,246:120-123. 被引量：1
8[7]Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med,1996,335:1001-1009. 被引量：1
9[8]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Survival Study (4S). Lancet,1994,344:1383-1389. 被引量：1
10[9]Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Eng J Med,1998,339:1349-1357. 被引量：1
